Leo Pharma's new drug for atopic dermatitis receives EU approval

Leo Pharma received a recommendation from the expert panel of the European Medicines Agency in April, and the commission has followed this advice, approving the eczema treatment Adtralza from the Danish company.

Photo: Leo Pharma / PR

Now, Leo Pharma can get properly started on launching the drug Adtralza in the EU.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs